17,261 trials
Bacterial Infection Due to Streptococcus, Group B · Streptococcus Agalactiae
Primary: Percentage of Subjects With ELISA Antibody Concentrations of GBS Serotype Ia Above Pre-specified Thresholds - Day 61 — 100; 100; 100; 100 Percentage of subjects
Acute Myeloid Leukemia With 11q23-abnormality in Relapse
Primary: Complete Remission (CR) — 0; 0 Participants
Anemia, Aplastic · Anemia, Hypoplastic · Thrombocytopenia
Primary: The Portion of Drug Responders as Defined by Hematologic Improvements — 17 Participants
Pulmonary Disease, Chronic Obstructive
Primary: Annual Rate of Moderate and Severe Exacerbations of COPD — 0.84; 0.88 Exacerbations per participant per year
Type 2 Diabetes Mellitus
Primary: Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM) — -4.94; -10.00; -1.21; -11.42 mg/dL…
Benzodiazepine Dependence · Opioid Dependence
Primary: Mean Reduction Change in Benzodiazepine Use Per Day Based on Time Line Follow Back — 4.0; 2.3 milligrams/day
Colorectal Neoplasms
Primary: The Number of Participants With Treatment-Related Adverse Events and Serious Adverse Events as a Measure of Safety — 25; 1 Participants
Prostatic Neoplasms
Primary: Number of Participants With an Event Defining SSE Free Survival - High Dose vs. Standard Dose — 85; 118 Participants
Head and Neck Cancer
Primary: Response Rate — 4 participants
Mucopolysaccharidosis IIIB
Primary: Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) — 1; 0; 1 Participants
Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Aggressive Non-Hodgkin Lymphoma
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0 Participants
Heart Failure
Primary: Characterize the Technical Feasibility of the Network Based IPC System — 72 percentage of days
Recurrent Small Cell Lung Cancer
Primary: Maximum Tolerated Dose (MTD) of Rovalpituzumab Tesirine — 0.4 mg/kg
Cocaine Dependence
Primary: Number of Participants Maintained on the Maximum Lisdexamfetamine Daily Dose. — 12 Participants
Aplastic Anemia
Primary: Number of Patients Having Attenuation of Accelerated Telomere Attrition — 12 Participants